Koers Refocus Group, Inc. Other OTC
Aandelen
RFCS
US75865X2027
Biotechnologie & Medisch Onderzoek
Omzet 2003 | - | Omzet 2004 | - | Marktkapitalisatie | 2,59 mln. 2,39 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2003 | -5 mln. -4,61 mln. | Nettowinst (verlies) 2004 | -3 mln. -2,77 mln. | EV/omzet 2003 | - |
Nettoliquiditeiten 2003 | 3 2,77 | Nettoschuld 2004 | 0,28 0,26 | EV/omzet 2004 | - |
K/w-verhouding 2003 |
-1,51
x | K/w-verhouding 2004 |
-0,67
x | Werknemers | - |
Dividendrendement 2003 * |
-
| Dividendrendement 2004 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
J. Michael Judy
CEO | Chief Executive Officer | - | 28-10-13 |
David Schanzlin
CTO | Chief Tech/Sci/R&D Officer | - | 01-02-12 |
Selene A. Burke
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-06 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 76 | 01-01-11 | |
Thomas M. Loarie
CHM | Chairman | - | 01-01-14 |
Thomas Lyles
BRD | Director/Board Member | - | 01-03-05 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+43,36% | 58,06 mld. | |
-5,31% | 40,53 mld. | |
+37,52% | 38,99 mld. | |
+14,75% | 26,7 mld. | |
-12,56% | 26,56 mld. | |
-22,45% | 18,98 mld. | |
+0,04% | 12,17 mld. | |
+25,12% | 12 mld. | |
+26,04% | 11,92 mld. |